Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Chronic Lymphocytic Leukemia: early-phase trial registry
9 of 21 indexed Recurrent Chronic Lymphocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 9 currently recruiting · #797 of 28,707 conditions by registered trial count
Recurrent Chronic Lymphocytic Leukemia: 21 US clinical trials tracked, 9 recruiting.
Recurrent Chronic Lymphocytic Leukemia is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition recurrent-chronic-lymphocytic-leukemia
OPEN 9 | RECR 43% | LATE 0 | EARLY 21 | RANK #797 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)
Recurrent Chronic Lymphocytic Leukemia lists 9 open slots (43% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Chronic Lymphocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Chronic Lymphocytic Leukemia is recruiting above its size-band peers.
9 of 21 indexed trials (42.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Chronic Lymphocytic Leukemia research.
M.D. Anderson Cancer Center accounts for 4 of 21 trials (19%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Chronic Lymphocytic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 24 among the 21 trials that report a genuine target (sentinel values excluded). 19 of those (90.5%) plan for fewer than 100 participants.
-
Recurrent Chronic Lymphocytic Leukemia research is mostly interventional.
21 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
NCT04169737
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Sumithira Vasu
NCT05418088
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
NCT06712810
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
NCT06191887
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Mayo Clinic
NCT04892277
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
NCT07166419
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
NCT07061951
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
NCT06839053
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Fred Hutchinson Cancer Center
NCT04941716
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02756897
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02007044
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
NCT03277729
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
City of Hope Medical Center
NCT02153580
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
NCT04007029
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
NCT04205409
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT03479268
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
City of Hope Medical Center
NCT03961672
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02160015
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
NCT01822509
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Steven E. Coutre
NCT03045328
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02530515
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Chronic Lymphocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Chronic Lymphocytic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Chronic Lymphocytic Leukemia page
21 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Recurrent Chronic Lymphocytic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Recurrent Chronic Lymphocytic Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Chronic Lymphocytic Leukemia condition card totals 21 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.